Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PSMD3 antisense RNA 1 (PSMD3-AS1) is a long noncoding antisense RNA transcribed from the opposite strand of the PSMD3 gene locus. Antisense RNAs, including PSMD3-AS1, are typically involved in gene expression regulation by base pairing with their cognate protein-coding mRNAs[3][6]. PSMD3-AS1 has recently been associated with diagnostic utility in diseases such as atherosclerotic renal artery stenosis[4]. Its precise biological functions and disease implications are under investigation, but as with other antisense lncRNAs, its regulatory potential makes it a candidate for future therapeutic or biomarker development[4][6].\n\nNo evidence currently links PSMD3-AS1 to specific drugs, mechanisms of action, or major safety concerns. Most available information is about its sequence, classification, genomic context, and initial disease association as a candidate biomarker.
Not applicable—no drugs currently listed for this target; lncRNAs often act through RNA–RNA interactions or modulation of gene expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PSMD3 antisense RNA 1 (PSMD3-AS1).